Clinical trials have shown that scientists may have finally found a breakthrough in combatting relapsing-remitting multiple sclerosis (MS). The treatments consist of a high dose immunosuppressive therapy coupled up with an implant of the patient’s blood-forming stem cells. This therapy has proven that it can lessen the effects of MS, a condition which causes the immune system to attack the nervous system.
69% of patients who tried the new drug have lived on without experiencing new MS symptoms, brain complications or advancement of neurological disability. The drug, called high-dose immunosuppressive therapy and autologous hematopoietic cell transplant (HDIT/HCT), has recorded a higher success rate than all of its competitors in the market.
The research was conducted by the National Institute of Allergy and Infectious Diseases (NIAID). Volunteers were MS patients between the age 26 and 52, who were taking other medications available which had adverse side effects to them. However, the use of HDIT/HCT proved to be safe and efficient.
The drug subdues the disease by removing the infected cell from the immune system. Doctors extract stem cells while administering the high dose therapy to suppress the immune system. The stem cells are then implanted back into the patient to reconstruct the immune system.
Realists showed massive improvements five years after taking the medication. Researchers aim to re-conduct the trial using a larger sample to increase the medication’s credibility. Although the therapy is still in its early stages, it has shown promise in the fight against MS.
Dr. Shiva’s Background
Dr. Shiva Gopal Vasishta is a neurologist based in Voorhees, New Jersey. He has practiced medicine for almost four decades. He graduated from Government Medical College in 1979.
Shiva Gopal Vasishta is a member of Medicare program hence he does not charge more than the approved amount if you are a Medicare member.
Additionally, Dr. Shiva Gopal Vasishta is an active member of the American board of psychiatry and neurology.